Archives from / to /


Cancer “checkpoint inhibitor” Immunotherapy Associated with Inflammatory Arthritis (March 30, 2017)

David Borenstein, MD Executive Editor theSpineCommunity Some of the recent advances in cancer therapy have enlisted our own immunity system to help kill cancer cells.  In usual circumstances, an immune... Continue Reading

FDA Approves Keytruda® for Adult and Pediatric Patients with Classical Hodgkin (March 29, 2017)

It was announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric... Continue Reading

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (March 28, 2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous... Continue Reading

Cancer “checkpoint inhibitor” Immunotherapy Associated with Inflammatory Arthritis (March 27, 2017)

David Borenstein, MD Executive Editor theSpineCommunity Some of the recent advances in cancer therapy have enlisted our own immunity system to help kill cancer cells.  In usual circumstances, an immune... Continue Reading

FDA Approves Keytruda® for Adult and Pediatric Patients with Classical Hodgkin (March 27, 2017)

It was announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric... Continue Reading

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (March 27, 2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous... Continue Reading

Goodbye Brain Fog! Strategies to Help Get Your Thinking Back on Track (March 27, 2017)

Have a Question about Cancer-Related Brain Fog? Ask the Expert! Live Web Chat Tuesday, March 28th, 4:00-5:00 PM, EST Tune in here. Join us for a live Ask the Expert session with neurocognitive expert Heather... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy... Continue Reading

Women&Cancer Magazine Features Paula Zahn on Spring 2008 Cover (March 22, 2017)

Women&Cancer Magazine Features Paula Zahn on Spring 2008 Cover March 17, 2008 Press Contact: Diana Price chweaver@omnihealthmedia.com (208) 727-2108, ext. 202 March... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (March 22, 2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival... Continue Reading

March is Multiple Myeloma Awareness Month: Learn About Recent Advances (March 21, 2017)

There are several recent advances of note in the management of all stages of Multiple Myeloma. Smoldering myeloma is considered to be a pre-cancerous condition, in which patients do not yet display any... Continue Reading

Lynparza Improves Progression-Free Survival in BRCA-Mutated Ovarian Cancer (March 21, 2017)

Results were recently presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, USA, demonstrating that Lynparza (olaparib) reduced the risk of platinum-sensitive,... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 20, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (March 20, 2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival... Continue Reading

Lynparza Improves Progression-Free Survival in BRCA-Mutated Ovarian Cancer (March 20, 2017)

Results were recently presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, USA, demonstrating that Lynparza (olaparib) reduced the risk of platinum-sensitive,... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS